BNOXBIONOMICS LIMITED/FI

Nasdaq bionomics.com.au


$ 0.65 $ -0.01 (-2.24 %)    

Tuesday, 17-Sep-2024 09:37:13 EDT
QQQ $ 473.45 $ -2.52 (-0.53 %)
DIA $ 417.37 $ -0.62 (-0.15 %)
SPY $ 562.92 $ -2.21 (-0.39 %)
TLT $ 100.98 $ -0.41 (-0.4 %)
GLD $ 237.43 $ -0.55 (-0.23 %)
$ 0.6649
$ 0.65
-- x --
-- x --
$ 0.65 - $ 0.65
$ 0.50 - $ 6.41
61,552
na
988.53M
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bionomics-receives-notice-of-allowance-for-us-patent-on-substituted-n-heteroaryl-compounds-for-cognitive-function-and-cns-disorders

https://patentcenter.uspto.gov/applications/17441637/ifw/docs

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-to-host-corporate-update-and-discuss-end-of-phase-2-meeting-outcomes-on-the-development-of-bnc210-in-ptsd-on-july-31-2024-at-800-am-et

Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class...

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-files-for-resale-of-up-to-364b-ordinary-shares-by-the-selling-shareholder

- SEC Filing 

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-reveals-detailed-data-from-ptsd-trial-stock-soars

Bionomics' Phase 2b ATTUNE trial on BNC210 for PTSD. Discover statistically significant improvements in symptom severity, c...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION